Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression